The 14-gene prognostic signature reported here was developed on untreated patient samples, and as suggested by one of the referees, one potential implication of the current study is that the 14-gene expression signature may identify a low-risk patient-group with hormone receptor-positive breast cancer, whose predicted absolute survival benefit from systemic adjuvant therapy is so low that a woman, armed with this prognostic information, may favor the avoidance of the occasionally troublesome side effects of endocrine therapy. Here, NR4A1 is linked to breast cancer.